Lantern Pharma and NCI expand oncology partnership
The latest move follows the identification of various gene signatures that predict a tumour’s possible response to these drug candidates of Lantern. LP-184 is being analysed as a
A once-weekly long-acting recombinant human growth hormone, somatrogon is intended for treating children from three years of age and adolescents experiencing growth disturbance because of inadequate secretion of